Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

carmustine

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

DNA synthesis inhibitor, Alkylating agent

Related drugs:

‹

cyclophosphamide intravenous (0)

cisplatin (330)

gemcitabine (181)

temozolomide (114)

cytarabine (99)

oxaliplatin (57)

dacarbazine (22)

cytarabine/daunorubicin liposomal formulation (19)

clofarabine (16)

temozolomide gel (7)

fludarabine IV (6)

hydroxyurea (3)

mercaptopurine (3)

fotemustine (2)

streptozocin (2)

fludarabine oral (2)

thioguanine (2)

fosgemcitabine palabenamide (1)

asparagine cytarabine conjugate (1)

gemcitabine intravesical system (1)

mitomycin urothelial gel (1)

melphalan hepatic delivery system (1)

liposomal cisplatin (0)

pegylated liposomal mitomycin-c prodrug (0)

mercaptopurine oral suspension (0)

gemcitabine with RenovoCath (0)

cytarabine ocfosfate (0)

mitomycin intravesicular (0)

captisol-enabled melphalan (0)

cyclophosphamide (66)

trabectedin (24)

lurbinectedin (11)

chlorambucil (7)

melphalan flufenamide (7)

procarbazine hydrochloride (4)

bendamustine RTD (2)

FGX15-147-based ADC (1)

bendamustine rapid infusion (0)

ranimustine (0)

carmustine implant (0)

altretamine (0)

mechlorethamine (0)

satraplatin (0)

mechlorethamine gel (0)

cyclophosphamide intravenous (0)

›

No biomarker	Astrocytoma	No biomarker	Astrocytoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Ependymoma	No biomarker	Ependymoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Medulloblastoma	No biomarker	Medulloblastoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Glioma	No biomarker	Glioma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2
IDH2 mutation	Astrocytoma	IDH2 mutation	Astrocytoma	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2